What are the best treatments for Chorea-acanthocytosis ChAc?

There is currently no cure for Chorea-acanthocytosis (ChAc), so treatment remains primarily symptomatic and supportive, focusing on managing movement disorders and neurological complications. Because Chorea-acanthocytosis (ChAc) is a progressive neurodegenerative condition, a multidisciplinary care team is essential to improve quality of life and address the complex needs of each patient.

How is Chorea-acanthocytosis (ChAc) managed medically?

Management of Chorea-acanthocytosis (ChAc) often involves a combination of pharmacotherapy to control involuntary movements and behavioral symptoms. Physicians may prescribe tetrabenazine (Xenazine) or dopamine receptor antagonists to help mitigate chorea. For patients experiencing dystonia, botulinum toxin injections are frequently utilized to provide localized relief. Additionally, anticonvulsants are necessary for the approximately 50% of patients who experience seizures during the course of the disease.

What non-pharmacological interventions are recommended?

Supportive therapies are critical for maintaining functional independence in Chorea-acanthocytosis (ChAc). A comprehensive rehabilitation plan typically includes:

• Physical Therapy: To maintain mobility, improve balance, and prevent falls.


• Occupational Therapy: To adapt daily living activities and provide assistive devices.


• Speech Therapy: To address oropharyngeal dyskinesia, which can cause significant difficulties with swallowing and speech.


• Nutritional Support: Gastrostomy tubes are sometimes required if severe dysphagia leads to malnutrition or aspiration risks.

Which specialists should be on the care team?

Due to the multisystem nature of Chorea-acanthocytosis (ChAc), care should be coordinated by a movement disorder neurologist. The team should ideally include a clinical geneticist, a psychiatrist for mood and cognitive changes, a physical therapist, and a swallowing specialist (speech-language pathologist). At DiseaseMaps.org, six members are currently sharing their experiences, highlighting the value of peer support in navigating this rare diagnosis.

Are there emerging treatments for Chorea-acanthocytosis (ChAc)?

Research into Chorea-acanthocytosis (ChAc) is ongoing, with current efforts focused on understanding the VPS13A protein deficiency. While there are no disease-modifying therapies currently approved, researchers are exploring gene therapy and small-molecule stabilizers in preclinical models. Participation in clinical trials remains the best way to access potential new therapies as they emerge.

Next steps

• Consult a movement disorder specialist at a major academic medical center.


• Connect with the Chorea-acanthocytosis (ChAc) community at DiseaseMaps.org to share experiences.


• Regularly screen for swallowing difficulties and cardiac function.


• Discuss genetic counseling with your team to understand the autosomal recessive inheritance pattern.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; treatment must be personalized by your healthcare team.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Chorea-acanthocytosis.


• Orphanet: Chorea-acanthocytosis (ORPHA:1396).


• OMIM (Online Mendelian Inheritance in Man): #200150.


• NCBI Bookshelf: GeneReviews for Chorea-Acanthocytosis.